Establishment and characterization of human pancreatic adenocarcinoma cell line in tissue culture and the nude mouse

Tissue and Cell

Volumn 39, Issue 4, 2007, Pages 217-223

  Kong, Dalu ^a   Nishino, Nobukazu ^b   Shibusawa, Miki ^b   Kusano, Mitsuo ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

CA19 9; DUPAN 2; Human cell line; Pancreatic ductal adenocarcinoma (PDAC); SPan 1

Indexed keywords

CA 19-9 ANTIGEN; DUPAN 2; SPAN 1 PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CELL POPULATION; CELL STRUCTURE; CHROMOSOME; CULTURE MEDIUM; CYTOGENETICS; CYTOLOGY; FETAL CALF SERUM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; SPLENECTOMY; TISSUE CULTURE; TUMOR MODEL;

MUS MUSCULUS;

EID: 34547700499     PISSN: 00408166     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tice.2007.04.001     Document Type: Article

References (17)

1. Arlt A., Vorndamm J., Müerkö ster S., Yu H., Schmidt W.E., Fölsch U.R., and Schäfer H. Autocrine production of interleukin 1 confers constitutive nuclear factor activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 62 (2002) 910-916
2. Carpelan-Holmström M., Nordling S., Pukkala E., Sankila R., Lüttges J., Klöppel G., and Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54 (2005) 385-387
3. Fong P., Argent B.E., Guggino W.B., and Gray M.A. Characterization of vectorial chloride transport pathways in the human pancreatic duct adenocarcinoma cell line HPAF. Am. J. Physiol. Cell Physiol. 285 (2003) C433-C445
4. Fukasawa M., and Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin. Cancer Res. 10 (2004) 3327-3332
5. Gangi S., Fletcher J.G., Nathan M.A., Christensen J.A., Harmsen W.S., Crownhart B.S., and Chari S.T. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. Am. J. Roentgenol. 182 (2004) 897-903
6. Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L., Veltman J.A., van Kessel A.G., and Höglund M. Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res. 64 (2004) 3052-3059
7. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer Statistics 2005. CA Cancer J. Clin. 55 (2005) 10-30
8. Jemal A., Siegel R., Ward E., Murray T., Xu J., Carpelan-Holmström Smigal C., and Thun M.J. Cancer Statistics 2006. CA Cancer J. Clin. 56 (2006) 106-130
9. McKenna S., and Eatock M. The medical management of pancreatic cancer: a review. Oncologist 8 (2003) 149-160
10. Miknyoczki S.J., Chang H., Klein-Szanto A., Dionne C.A., and Ruggeri B.A. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft modelsof human pancreatic ductal adenocarcinoma. Clin. Cancer Res. 5 (1999) 2205-2212
11. Mitelman, F., S. Karger, Basel. ISCN 1995: An international system for human cytogenetic nomenclature.
12. Rosty C., Ueki T., Argani P., Jansen M., Yeo C.J., Cameron J.L., Hruban R.H., and Goggins M. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 160 (2002) 45-50
13. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., Hruban R.H., and Goggins M. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 63 (2003) 3735-3742
14. Schlieman M.G., Ho H.S., and Bold R.J. Utility of tumor markers in determining resectability of pancreatic cancer. Arch. Surg. 138 (2003) 951-956
15. Takhar A.S., Palaniappan P., Dhingsa R., and Lobo D.N. Recent developments in diagnosis of pancreatic cancer. BMJ 329 (2004) 668-673
16. Ueki T., Toyota M., Skinne H.r., Walter K.M., Yeo C.J., Issa J.P., Hruban R.H., and Goggins M. Identification and characterization of differentially methylated CpG Islands in pancreatic carcinoma. Cancer Res. 61 (2001) 8540-8546
17. Yamano M., Fujii H., Takagaki T., Kadowaki N., Watanabe H., and Shirai T. Genetic progression and divergence in pancreatic carcinoma. Am. J. Pathbol. 156 6 (2000) 2123-2133